Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
McKinsey
QuintilesIMS
Cipla
Julphar
Queensland Health
Daiichi Sankyo
Mallinckrodt

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FERRIC PYROPHOSPHATE CITRATE

« Back to Dashboard

Clinical Trials for Ferric Pyrophosphate Citrate

Trial ID Title Status Sponsor Phase Summary
NCT02595437 Triferic Pediatric Pharmacokinetic Protocol Recruiting Rockwell Medical Technologies, Inc. Phase 1/Phase 2 The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.
NCT02636049 Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers Completed Rockwell Medical Technologies, Inc. Phase 1 This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
NCT02739100 Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Completed Rockwell Medical Technologies, Inc. Phase 1 The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered via hemodialysate and via two different intravenous routes in adult patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, randomized single dose study.
NCT02767128 Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers Completed Rockwell Medical Technologies, Inc. Phase 1 The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered orally in healthy adult volunteers. It is a randomized multiple treatments, single dose study.
NCT02905981 Triferic IRIDA Protocol Not yet recruiting Rockwell Medical Technologies, Inc. Phase 2 The main purpose is to determine whether Triferic, administered orally with Shohl's solution, is safe and effective for the treatment of iron-refractory iron-deficiency anemia (IRIDA).
NCT02909153 Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis Not yet recruiting Rockwell Medical Technologies, Inc. Phase 1 The main purpose is to determine the pharmacokinetic (PK) profile, maximum concentration (Cmax) and Area Under the Concentration Time Curve (AUC0-t) of Triferic iron administered intraperitoneally in patients with chronic kidney disease on peritoneal dialysis (CKD-5 PD). It is an open label, dose escalation study.
NCT03303144 Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Not yet recruiting Rockwell Medical Technologies, Inc. Phase 1/Phase 2 The main purpose is to establish the equivalence of Triferic iron administered via dialysate into the arterial blood line and into the venous blood line
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ferric Pyrophosphate Citrate

Condition Name

Condition Name for Ferric Pyrophosphate Citrate
Intervention Trials
End Stage Renal Disease 4
Chronic Kidney Disease 1
Anemia 1
Peritoneal Dialysis (PD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ferric Pyrophosphate Citrate
Intervention Trials
Kidney Failure, Chronic 4
Anemia, Iron-Deficiency 2
Kidney Diseases 1
Deficiency Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ferric Pyrophosphate Citrate

Trials by Country

Trials by Country for Ferric Pyrophosphate Citrate
Location Trials
United States 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ferric Pyrophosphate Citrate
Location Trials
Michigan 2
Florida 2
Texas 1
Ohio 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ferric Pyrophosphate Citrate

Clinical Trial Phase

Clinical Trial Phase for Ferric Pyrophosphate Citrate
Clinical Trial Phase Trials
Phase 2 1
Phase 1/Phase 2 2
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ferric Pyrophosphate Citrate
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ferric Pyrophosphate Citrate

Sponsor Name

Sponsor Name for Ferric Pyrophosphate Citrate
Sponsor Trials
Rockwell Medical Technologies, Inc. 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ferric Pyrophosphate Citrate
Sponsor Trials
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Chubb
Covington
Boehringer Ingelheim
Baxter
Teva
Harvard Business School
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.